摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-methyl-5-(o-tolyl)-1,2,4-oxadiazole | 1119448-03-1

中文名称
——
中文别名
——
英文名称
3-methyl-5-(o-tolyl)-1,2,4-oxadiazole
英文别名
3-Methyl-5-(2-methylphenyl)-1,2,4-oxadiazole
3-methyl-5-(o-tolyl)-1,2,4-oxadiazole化学式
CAS
1119448-03-1
化学式
C10H10N2O
mdl
MFCD13961845
分子量
174.202
InChiKey
HTCZLPRRVGFOFM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    300.3±35.0 °C(Predicted)
  • 密度:
    1.113±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    邻甲基苯甲酰氯 在 magnesium sulfate 、 三乙胺三氟乙酸 作用下, 以 乙醚 为溶剂, 反应 6.0h, 生成 3-methyl-5-(o-tolyl)-1,2,4-oxadiazole
    参考文献:
    名称:
    TFA 介导的氨基甲酸酯和腈合成 1,2,4-恶二唑
    摘要:
    通过使用腈作为底物和溶剂,开发了一种从氨基甲酸酯合成 1,2,4-恶二唑的前所未有的方案。这一一锅法通过 TFA 介导的 [3+2] 环化实现了 C=N 键的形成。以中等至良好的收率合成了一系列 1,2,4-恶二唑。
    DOI:
    10.1021/acs.joc.4c00640
点击查看最新优质反应信息

文献信息

  • Construction of 3,5-substituted 1,2,4-oxadiazole rings triggered by tetrabutylammonium hydroxide: a highly efficient and fluoride-free ring closure reaction of O-acylamidoximes
    作者:Hiromichi Otaka、Junya Ikeda、Daisuke Tanaka、Masanori Tobe
    DOI:10.1016/j.tetlet.2013.12.016
    日期:2014.1
    Tetrabutylammonium hydroxide (TBAH) is an efficient and mild alternative to tetrabutylammonium fluoride (TBAF) for base catalyzed cyclizations of 1,2,4-oxadiazoles from O-acylamidoximes. For most 3,5-substituted 1,2,4-oxadiazoles the reactions were dramatically accelerated by addition of 0.1 equiv of TBAH at room temperature. This method was also more generally applicable allowing for a wider range
    氢氧化四丁基(TBAH)是化四丁基(TBAF)的一种高效,温和的替代品,用于由O-酰基酰胺基1,2,4-恶二唑进行碱催化的环化反应。对于大多数3,5-取代的1,2,4-恶二唑,在室温下通过添加0.1当量的TBAH可以显着加速反应。该方法也更普遍地适用于允许更大范围的基板。另外,由于不存在化物,TBAH不会导致反应堆容器的腐蚀,因此更适合大规模合成。
  • PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS
    申请人:Gilead Sciences, Inc.
    公开号:US20130164280A1
    公开(公告)日:2013-06-27
    The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.
    该发明提供了用于治疗病毒感染的化合物、药物可接受的盐和酯以及它们的组合物。这些化合物和组合物对于治疗包括人类呼吸道合胞病毒感染在内的肺病毒亚科病毒感染是有用的。
  • BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    申请人:Katayama Seiji
    公开号:US20130116227A1
    公开(公告)日:2013-05-09
    Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R 1 is a substitutable aminosulfonyl group, etc.; R 2 is a hydrogen atom, etc.; R 3 is a hydrogen atom, etc.; R 4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C 1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R 5a , R 5b and R 5c are each independently hydrogen atoms, etc.; R 6 is a halogen atom, a cyano group, etc.; R 7 and R 8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.)
    揭示了一种表示为公式(1)的新型联苯酰胺衍生物,具有与醛固酮受体的亲和力;还揭示了其药用可接受的盐。(在该公式中,A是由公式(a)表示的任何基团之一;L是—CONH—等;R1是可替代的基磺酰基等;R2是氢原子等;R3是氢原子等;R4是氢原子、卤原子、羟基、可替代的基基团、可替代的C1-6烷氧基、可替代的4-到7-成员环基基团等;R5a、R5b和R5c各自独立地是氢原子等;R6是卤原子、基等;R7和R8各自独立地是氢原子等;m是整数,例如0。)
  • [EN] 2-(2-AZABICYCLO[3.1.0]HEXAN-1-YL)-1H-BENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-(2-AZABICYCLO [3.1.0] HEXAN-1-YL)-1H-BENZIMIDAZOLE
    申请人:IDORSIA PHARMACEUTICALS LTD
    公开号:WO2020007964A1
    公开(公告)日:2020-01-09
    The present invention relates to compounds of the Formula (I) wherein Ar1, R1, and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as orexin receptor antagonists.
    本发明涉及式(I)的化合物,其中Ar1,R1和(R5)n如描述中所述,以及它们的制备,其药学上可接受的盐,以及它们作为药物的用途,包括含有一种或多种式(I)化合物的药物组合物,特别是它们作为促进睡眠的奥莱欣受体拮抗剂的用途。
  • [EN] OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE, QUI SONT DES DÉRIVÉS [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2014057435A1
    公开(公告)日:2014-04-17
    The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    本发明涉及公式(I)中的[ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-甲酮衍生物,其中R和环A1、A2和A3如描述中所述,以及其药用盐,其制备方法,含有一个或多个公式(I)化合物的药物组合物,以及它们作为药物的用途,特别是作为促进睡眠荷尔蒙受体拮抗剂的用途。
查看更多